Contax Participações S.A. (BVMF:CTAX3)

Verve Therapeutics Ratios and Metrics

Market cap in millions BRL. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	28	33	120	34	69	57
Market Cap Growth	-41.67%	-72.89%	251.56%	-50.77%	22.39%	126.90%
Enterprise Value	191	216	281	305	353	421
Last Close Price	1.06	1.22	4.50	1.28	2.60	2.30
PE Ratio	-	-	0.20	-	-	-
Forward PE	-	0.66	0.66	0.66	0.66	0.66
PS Ratio	0.07	0.09	0.39	0.05	0.07	0.06
PB Ratio	0.26	0.22	0.41	-0.11	0.45	0.34
P/FCF Ratio	3.17	3.35	-	0.31	1.79	1.23
P/OCF Ratio	3.17	3.30	-	0.30	1.54	1.13
EV/Sales Ratio	0.49	0.58	0.92	0.45	0.34	0.45
EV/EBITDA Ratio	-	19.58	-	-	132.80	-
EV/FCF Ratio	21.36	22.16	-	2.73	9.09	9.12
Debt / Equity Ratio	2.15	1.52	0.80	-1.33	2.17	1.90
Debt / EBITDA Ratio	-	13.32	-	-	14.61	-
Debt / FCF Ratio	25.87	23.31	-	3.56	8.65	6.86
Asset Turnover	0.32	0.29	0.20	0.39	0.59	0.61
Quick Ratio	0.35	0.38	0.81	0.31	0.34	0.43
Current Ratio	0.38	0.41	0.86	0.32	0.42	0.48
Return on Equity (ROE)	-118.50%	-64.08%	-	-	-84.72%	-26294.18%
Return on Assets (ROA)	-2.19%	-1.61%	-8.72%	-6.44%	-1.98%	-4.49%
Return on Capital (ROIC)	-5.42%	-4.55%	-44.25%	-37.98%	-7.21%	-18.06%
Earnings Yield	-1102.73%	-431.99%	490.86%	-1331.64%	-196.25%	-378.41%
FCF Yield	31.54%	29.89%	-31.04%	327.36%	55.93%	81.44%
Buyback Yield / Dilution	-	-	-	-	-13.87%	-1187.46%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.